Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
(2025) In QJM - Monthly Journal of the Association of Physicians 118(1). p.3-4
    Please use this url to cite or link to this publication:
    https://lup.lub.lu.se/record/834f54e1-4dba-4cb3-a031-2f6418b8303f
- author
- Hakariya, Hayase ; Ozaki, Akihiko ; Mulinari, Shai LU ; Moriarty, Frank and Tanimoto, Tetsuya
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- in
- QJM - Monthly Journal of the Association of Physicians
- volume
- 118
- issue
- 1
- pages
- 3 - 4
- publisher
- Oxford University Press
- external identifiers
- 
                - pmid:38867701
- scopus:85198074596
 
- ISSN
- 0033-5622
- DOI
- 10.1093/qjmed/hcae115
- language
- English
- LU publication?
- yes
- id
- 834f54e1-4dba-4cb3-a031-2f6418b8303f
- date added to LUP
- 2024-06-13 16:09:40
- date last changed
- 2025-10-27 17:03:54
@article{834f54e1-4dba-4cb3-a031-2f6418b8303f,
  author       = {{Hakariya, Hayase and Ozaki, Akihiko and Mulinari, Shai and Moriarty, Frank and Tanimoto, Tetsuya}},
  issn         = {{0033-5622}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{3--4}},
  publisher    = {{Oxford University Press}},
  series       = {{QJM - Monthly Journal of the Association of Physicians}},
  title        = {{Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval}},
  url          = {{http://dx.doi.org/10.1093/qjmed/hcae115}},
  doi          = {{10.1093/qjmed/hcae115}},
  volume       = {{118}},
  year         = {{2025}},
}